Microbiome venture can start production in Denmark and Switzerland

The Danish Medicines agency has inspected Bacthera, a joint venture between Danish enzyme giant Chr. Hansen and Swiss Lonza, and has authorized the company to start producing bacteria for medical purposes in Denmark. The Swiss health authorities have also given the go-ahead.

Photo: Lonza / PR

Bioscience company Chr. Hansen and Swiss biotech firm Lonza have obtained permission to launch the production of bacteria for pharmaceutical use in their production facilities in Denmark and Switzerland.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs